Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
The aim of the study is to evaluate, after radiological progression, efficacy in patients treated with Sorafenib at a dose of 600 mg bid compared to that in patients treated with best supportive care.

Primary efficacy objective is progression free survival from randomization.
Carcinoma, Hepatocellular
DRUG: Sorafenib (BAY-43-9006)
The aim of the study is to evaluate, after radiological progression, efficacy in patients treated with Sorafenib at a dose of 600 mg bid compared to that in patients treated with best supportive care.

Primary efficacy objective is progression free survival from randomization.